Recent Analysts' Ratings Changes for Vanda Pharmaceuticals


11/17/2018 - Vanda Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $26.00 price target on the stock.



from Biotech News